The FDA has given its sanction for Wezlana (ustekinumab-auub), considering it a biosimilar and substitute for Stelara (ustekinumab) in treating several inflammatory conditions.

In a hairpin sequence, the strand loops out and then come back to pair with itself, forming a double helix (the stem) ending in an unpaired loop.

The U.S. Food and Drug Administration (FDA) has given permission to resume the Phase 1 clinical trial of XMT-2056, according to Mersana Therapeutics, Inc., a biopharmaceutical firm in the clinical stage.

This article summarized the latest R&D progress of Midodrine Hydrochloride, the Mechanism of Action for Midodrine Hydrochloride, and the drug target R&D trends for Midodrine Hydrochloride.

Lirum Therapeutics announces encouraging results on LX-101, an innovative, clinical-phase targeted treatment, showing significant preliminary efficacy against children's sarcomas.

A fusion protein is a protein composed of at least two domains that are encoded by separate genes fused together so that they are transcribed and translated as a single unit, producing a single polypeptide.

Context Therapeutics has revealed promising preclinical results for its research asset, CTIM-76.

This article summarized the latest R&D progress of Glycyrrhetinic Acid, the mechanism of action for Glycyrrhetinic Acid, and the drug target R&D trends for Glycyrrhetinic Acid.

Chimeric Therapeutics has disclosed that the US FDA has given the green light to the IND submission for CHM 2101.

According to the Patsnap Bio Sequence Database, the top 10 applicants for the Vyjuvek patent are Krystal Biotech with 32 applications, Holostem Terapie Avanzate Srl with 6 applications, and FONDATION A DE ROTHSCHILD with 2 applications.

AceLink Therapeutics announced the initiation of AL01211 dosage for the first patient in its Phase 2 study for Fabry disease in China.

This article summarized the latest R&D progress of Halcinonide, the Mechanism of Action for Halcinonide, and the drug target R&D trends for Halcinonide.